Tel: 0755-85269922 E-mail: sales@biochemmall.com
ICP:粤ICP备19135875号
Riociguat, also known as BAY 63-2521, is a novel drug that is currently in clinical development by Bayer. It is a stimulator of soluble guanylate cyclase (sGC). At the moment Phase III clinical trials investigate the use of riociguat as a new approach to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of a novel class of sGC stimulators.
Brand: BCM
Melting Point: 247-251°C (dec.)
Solubility: Soluble in DMSO. Insoluble in Water.
InChi Key: WXXSNCNJFUAIDG-UHFFFAOYSA-N
Attribute [CAS No.] 625115-55-1 [Formula] C20H19FN8O2 [Molecular] 422.43 [Chem Name] Methyl(4,6-diaMino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyriMidin-5-yl)(Methyl)carbaMate [Synonym] BAY 63-2521; BAY63-2521; BAY632521; Riociguat [Storage] Refrigerator [EINECS] 641-755-1 [MDL No.] MFCD19443708 [Form] Off-White to Orange Solid
Goods Tag